Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OX640 is a powder-based, intranasal epinephrine (adrenaline) rescue medication developed for the acute treatment of severe allergic reactions, including anaphylaxis. It utilizes Orexo’s proprietary AmorphOX drug delivery platform, which enables rapid systemic absorption of epinephrine after nasal administration and offers improved physical and chemical stability compared to traditional injectable formulations. The product is designed as a needle-free alternative to auto-injectors, providing greater convenience, longer shelf life, and more flexible storage conditions. Clinical studies have shown that OX640 achieves clinically relevant plasma levels of epinephrine more rapidly than intramuscular injection products—even in patients with allergic rhinitis—supporting its use as a fast-acting emergency therapy for anaphylaxis[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OX640.